Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-03-21

Clinical Trial Update: Risperidone for the Treatment of Huntington's Disease Involuntary Movements [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating risperidone for involuntary movements in Huntington's disease (chorea) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • RISPERIDONE (RISPERIDONE)

Snippet

Sponsor: University of Rochester | Conditions: Huntington Disease, Chorea | Phase 2 | Status: COMPLETED | Results posted: 2025-03-21